Skip to main content
SpringerLink
Log in

Medikamentös-toxischer Leberschaden (DILI)

  • Chapter
  • First Online:
Pathologie

Part of the book series: Pathologie ((PATHOL))

  • 3912 Accesses

Zusammenfassung

Das Kapitel über den medikamentös-toxischen Leberschaden beschreibt die häufigsten Formen der Leberschäden, die durch verordnete oder frei erhältliche Medikamente, Heilkräuter oder Nahrungsmittelzusätze verursacht werden. Der erste Teil fasst die unterschiedlichen Pathomechanismen zusammen. Im zweiten Teil werden die medikamentös-toxische Autoimmunhepatitis, Steatose und Steatohepatitis sowie Fibrose und Cholestase dargestellt. Der Bezug der histopathologischen Muster zu den einzelnen Medikamenten, Heilkräutern oder Nahrungsmittelzusätzen wird tabellarisch zusammengefasst.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 309.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Abe M, Furukawa S, Takayama S, Michitaka K, Minami H, Yamamoto K, Horiike N et al (2003) Drug-induced hepatitis with autoimmune features during minocycline therapy. Intern Med 42:48–52

    PubMed  Google Scholar 

  2. Abraham C, Hart J, Locke SM, Baker AL (2008) A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 5:172–176

    PubMed  Google Scholar 

  3. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H (2010) Mechanisms of immune-mediated liver injury. Toxicol Sci 115:307–321

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK (2009) NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 104:861–867

    PubMed  Google Scholar 

  5. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O (2010) Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 44:e20–e22

    PubMed  Google Scholar 

  6. Adler E, Benjamin SB, Zimmerman HJ (1986) Cholestatic hepatic injury related to warfarin exposure. Arch Intern Med 146:1837–1839

    CAS  PubMed  Google Scholar 

  7. Agarwal K, Manas DM, Hudson M (1999) Terbinafine and fulminant hepatic failure. N Engl J Med 340:1292–1293

    CAS  PubMed  Google Scholar 

  8. Agarwal VK, McHutchison JG, Hoofnagle JH (2010) Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 8:463–470

    PubMed  PubMed Central  Google Scholar 

  9. Ahmed F, Petrovic L, Rosen E, Gonzalez R, Jacobson IM (2005) Fenofibrate-induced cirrhosis. Dig Dis Sci 50:312–313

    PubMed  Google Scholar 

  10. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, Kenna JG et al (2004) Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39:1430–1440

    CAS  PubMed  Google Scholar 

  11. Aithal PG, Day CP (1999) The natural history of histologically proved drug induced liver disease. Gut 44:731–735

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A (2007) Imatinib-induced immune hepatitis: case report and literature review. Hematology 12:49–53

    PubMed  Google Scholar 

  13. Alazmi WM, McHenry L, Watkins JL, Fogel EL, Schmidt S, Sherman S, Lehman GL (2006) Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy. J Clin Gastroenterol 40:353–357

    PubMed  Google Scholar 

  14. Aliberti S, Grignani G, Allione P, Fizzotti M, Galatola G, Pisacane A, Aglietta M (2009) An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient. Am J Clin Oncol 32:640–641

    PubMed  Google Scholar 

  15. Altintas E, Oguz D, Kacar S, Ozderin Y, Sezgin O, Zengin NI (2004) Dydrogesterone-induced hepatitis and autoimmune hemolytic anemia. Turk J Gastroenterol 15:49–52

    PubMed  Google Scholar 

  16. Altraif I, Lilly L, Wanless IR, Heathcote J (1994) Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. Am J Gastroenterol 89:1230–1234

    CAS  PubMed  Google Scholar 

  17. Amit G, Cohen P, Ackerman Z (2002) Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 4:184–186

    PubMed  Google Scholar 

  18. Anand BS (1999) Cirrhosis of liver. West J Med 171:110–115

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Andrade RJ, Guilarte J, Salmeron FJ, Lucena MI, Bellot V (2001) Benzylpenicillin-induced prolonged cholestasis. Ann Pharmacother 35:783–784

    CAS  PubMed  Google Scholar 

  20. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, Garcia-Munoz B et al (2005) Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129:512–521

    PubMed  Google Scholar 

  21. Andrade RJ, Lucena MI, Kaplowitz N, Garcia-Munoz B, Borraz Y, Pachkoria K, Garcia-Cortes M et al (2006) Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 44:1581–1588

    CAS  PubMed  Google Scholar 

  22. Angulo JM, Sigal LH, Espinoza LR (1999) Minocycline induced lupus and autoimmune hepatitis. J Rheumatol 26:1420–1421

    CAS  PubMed  Google Scholar 

  23. Appleyard S, Saraswati R, Gorard DA (2010) Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Rep 4:311

    PubMed  PubMed Central  Google Scholar 

  24. Arranto AJ, Sotaniemi EA (1981) Histologic follow-up of alpha-methyldopa-induced liver injury. Scand J Gastroenterol 16:865–872

    CAS  PubMed  Google Scholar 

  25. Aslan AN, Sar C, Bastug S, Sar SO, Akcay M, Durmaz T, Bozkurt E (2016) Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. Blood Coagul Fibrinolysis 27:226–227

    CAS  PubMed  Google Scholar 

  26. Avasthi G, Bhatt P, Singh J (2012) Methotrexate-induced liver cirrhosis in a patient of psoriasis. J Assoc Physicians India 60:47–48

    PubMed  Google Scholar 

  27. Babany G, Larrey D, Pessayre D, Degott C, Rueff B, Benhamou JP (1987) Chronic active hepatitis caused by benzarone. J Hepatol 5:332–335

    CAS  PubMed  Google Scholar 

  28. Bachmeyer C, Cadranel JF (2002) Minocycline-induced lupus and autoimmune hepatitis: family autoimmune disorders as possible risk factors. Dermatology 205:185–186

    CAS  PubMed  Google Scholar 

  29. Banks AT, Zimmerman HJ, Ishak KG, Harter JG (1995) Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology 22:820–827

    CAS  PubMed  Google Scholar 

  30. Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, Ponce J (2005) Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 22:775–782

    CAS  PubMed  Google Scholar 

  31. Batts KP, Ludwig J (1995) Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 19:1409–1417

    CAS  PubMed  Google Scholar 

  32. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, Leroux JP et al (1987) Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A 84:551–555

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Beaune PH, Bourdi M (1993) Autoantibodies against cytochromes P-450 in drug-induced autoimmune hepatitis. Ann N Y Acad Sci 685:641–645

    CAS  PubMed  Google Scholar 

  34. Beaune PH, Lecoeur S, Bourdi M, Gauffre A, Belloc C, Dansette P, Mansuy D (1996) Anti-cytochrome P450 autoantibodies in drug-induced disease. Eur J Haematol Suppl 60:89–92

    CAS  PubMed  Google Scholar 

  35. Bedoucha M, Atzpodien E, Boelsterli UA (2001) Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 35:17–23

    CAS  PubMed  Google Scholar 

  36. Belloc C, Gauffre A, Andre C, Beaune PH (1997) Epitope mapping of human CYP1A2 in dihydralazine-induced autoimmune hepatitis. Pharmacogenetics 7:181–186

    CAS  PubMed  Google Scholar 

  37. Yahia BM, Mavier P, Metreau JM, Zafrani ES, Fabre M, Gatineau-Saillant G, Dhumeaux D et al (1993) Chronic active hepatitis and cirrhosis induced by wild germander. 3 cases. Gastroenterol Clin Biol 17:959–962

    PubMed  Google Scholar 

  38. Benichou C (1990) Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 11:272–276

    CAS  PubMed  Google Scholar 

  39. Berends MA, van Oijen MG, Snoek J, van de Kerkhof PC, Drenth JP, Han van Krieken J, de Jong EM (2007) Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol 143:1515–1519

    CAS  PubMed  Google Scholar 

  40. Bernard PH, Lamouliatte H, Le Bail B, Bioulac-Sage P, Quinton A, Balabaud C (1994) Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate. Gastroenterol Clin Biol 18:1048–1049

    CAS  PubMed  Google Scholar 

  41. Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, Verthier N et al (1998) Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114:764–774

    CAS  PubMed  Google Scholar 

  42. Bhat G, Jordan J Jr., Sokalski S, Bajaj V, Marshall R, Berkelhammer C (1998) Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol 27:74–75

    CAS  PubMed  Google Scholar 

  43. Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH (2001) Drug-induced liver injury: mechanisms and test systems. Hepatology 33:1009–1013

    CAS  PubMed  Google Scholar 

  44. Bjornsson E, Davidsdottir L (2009) The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 50:511–517

    PubMed  Google Scholar 

  45. Bjornsson E, Olsson R (2005) Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42:481–489

    PubMed  Google Scholar 

  46. Bjornsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M et al (2010) Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 51:2040–2048

    PubMed  Google Scholar 

  47. Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S (2013) Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 144:1419–1425.e3 (quiz e1419–1420)

    PubMed  Google Scholar 

  48. Bjornsson ES, Jonasson JG (2013) Drug-induced cholestasis. Clin Liver Dis 17:191–209

    PubMed  Google Scholar 

  49. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR (1975) Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69:289–302

    CAS  PubMed  Google Scholar 

  50. Borum ML (2001) Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol 96:1654–1655

    CAS  PubMed  Google Scholar 

  51. Bourdi M, Gautier JC, Mircheva J, Larrey D, Guillouzo A, Andre C, Belloc C et al (1992) Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug. Mol Pharmacol 42:280–285

    CAS  PubMed  Google Scholar 

  52. Bourdi M, Tinel M, Beaune PH, Pessayre D (1994) Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol Pharmacol 45:1287–1295

    CAS  PubMed  Google Scholar 

  53. Brabec V, Kasparkova J (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8:131–146

    CAS  PubMed  Google Scholar 

  54. Brau N, Leaf HL, Wieczorek RL, Margolis DM (1997) Severe hepatitis in three AIDS patients treated with indinavir. Lancet 349:924–925

    CAS  PubMed  Google Scholar 

  55. Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB (2009) Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49:250–257

    PubMed  Google Scholar 

  56. Brown BA, Wallace RJ Jr., Griffith DE, Girard W (1995) Clarithromycin-induced hepatotoxicity. Clin Infect Dis 20:1073–1074

    CAS  PubMed  Google Scholar 

  57. Bruguera M, Pares A, Heredia D, Rodes J (1987) Cyanamide hepatotoxicity. Incidence and clinico-pathological features. Liver 7:216–222

    CAS  PubMed  Google Scholar 

  58. Brunt EM (2009) Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 13:533–544

    PubMed  Google Scholar 

  59. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474

    CAS  PubMed  Google Scholar 

  60. Buchweitz JP, Ganey PE, Bursian SJ, Roth RA (2002) Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 300:460–467

    CAS  PubMed  Google Scholar 

  61. Burt AD, Mutton A, Day CP (1998) Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 15:246–258

    CAS  PubMed  Google Scholar 

  62. Castera L, Kalinsky E, Bedossa P, Tertian G, Buffet C (1999) Macrovesicular steatosis induced by interferon alfa therapy for chronic myelogenous leukaemia. Liver 19:259–260

    CAS  PubMed  Google Scholar 

  63. Chalasani N, Bjornsson E (2010) Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 138:2246–2259

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H et al (2008) Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 135:1924–1934.e4

    PubMed  PubMed Central  Google Scholar 

  65. Chang CC, Petrelli M, Tomashefski JF Jr., McCullough AJ (1999) Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med 123:251–256

    CAS  PubMed  Google Scholar 

  66. Chang CY, Schiano TD (2007) Review article: drug hepatotoxicity. Aliment Pharmacol Ther 25:1135–1151

    CAS  PubMed  Google Scholar 

  67. Choi GY, Yang HW, Cho SH, Kang DW, Go H, Lee WC, Lee YJ et al (2008) Acute drug-induced hepatitis caused by albendazole. J Korean Med Sci 23:903–905

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Christen U, Quinn J, Yeaman SJ, Kenna JG, Clarke JB, Gandolfi AJ, Gut J (1994) Identification of the dihydrolipoamide acetyltransferase subunit of the human pyruvate dehydrogenase complex as an autoantigen in halothane hepatitis. Molecular mimicry of trifluoroacetyl-lysine by lipoic acid. Eur J Biochem 223:1035–1047

    CAS  PubMed  Google Scholar 

  69. Cohen SM, O’Connor AM, Hart J, Merel NH, Te HS (2004) Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause 11:575–577

    PubMed  Google Scholar 

  70. Colombo C, Vajro P, Degiorgio D, Coviello DA, Costantino L, Tornillo L, Motta V et al (2011) Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations. J Pediatr Gastroenterol Nutr 52:73–83

    CAS  PubMed  Google Scholar 

  71. Cotreau MM, von Moltke LL, Greenblatt DJ (2005) The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 44:33–60

    CAS  PubMed  Google Scholar 

  72. Czaja AJ (2008) Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol 6:379–388

    CAS  PubMed  Google Scholar 

  73. Czaja AJ (2011) Drug-induced autoimmune-like hepatitis. Dig Dis Sci 56:958–976

    CAS  PubMed  Google Scholar 

  74. Czaja AJ (2013) Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci 58:897–914

    CAS  PubMed  Google Scholar 

  75. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP (2007) Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132:272–281

    CAS  PubMed  Google Scholar 

  76. Dancygier H (2001) Nonalcoholic steatohepatitis. Dtsch Med Wochenschr 126:930

    CAS  PubMed  Google Scholar 

  77. Dang LJ, Lubel JS, Gunatheesan S, Hosking P, Su J (2014) Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis. Australas J Dermatol 55:75–79

    PubMed  Google Scholar 

  78. Dansette PM, Bonierbale E, Minoletti C, Beaune PH, Pessayre D, Mansuy D (1998) Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet 23:443–451

    CAS  PubMed  Google Scholar 

  79. Davies MG, Kersey PJ (1989) Acute hepatitis and exfoliative dermatitis associated with minocycline. BMJ 298:1523–1524

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Davies MH, Harrison RF, Elias E, Hubscher SG (1994) Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 20:112–116

    CAS  PubMed  Google Scholar 

  81. de Araujo MS, Gerard F, Chossegros P, Porto LC, Barlet P, Grimaud JA (1990) Vascular hepatotoxicity related to heroin addiction. Virchows Arch A Pathol Anat Histopathol 417:497–503

    PubMed  Google Scholar 

  82. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, Moreau A et al (1992) Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 15:244–251

    CAS  PubMed  Google Scholar 

  83. DeLeve LD, Ito Y, Bethea NW, McCuskey MK, Wang X, McCuskey RS (2003) Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastrointest Liver Physiol 284:G1045–G1052

    CAS  PubMed  Google Scholar 

  84. DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK, Tokes ZA et al (2003) Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 38:900–908

    CAS  PubMed  Google Scholar 

  85. Deng X, Stachlewitz RF, Liguori MJ, Blomme EA, Waring JF, Luyendyk JP, Maddox JF et al (2006) Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 319:1191–1199

    CAS  PubMed  Google Scholar 

  86. Dhalluin-Venier V, Besson C, Dimet S, Thirot-Bibault A, Tchernia G, Buffet C (2006) Imatinib mesylate-induced acute hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 18:1235–1237

    CAS  PubMed  Google Scholar 

  87. Dienes HP, Drebber U (2010) Pathology of immune-mediated liver injury. Dig Dis 28:57–62

    PubMed  Google Scholar 

  88. Dietrichson O, Juhl E, Nielsen JO, Oxlund JJ, Christoffersen P (1974) The incidence of oxyphenisatin-induced liver damage in chronic non-alcoholic liver disease. A controlled investigation. Scand J Gastroenterol 9:473–478

    CAS  PubMed  Google Scholar 

  89. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP et al (2010) Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 53:1049–1053

    CAS  PubMed  Google Scholar 

  90. Droste HT, de Vries RA (1995) Chronic hepatitis caused by lisinopril. Neth J Med 46:95–98

    CAS  PubMed  Google Scholar 

  91. Duburque C, Bonnal JL, Gosset P, Lucidarme D (2012) Could gosereline acetate induce autoimmune-like hepatitis? Prog Urol 22:610–612

    CAS  PubMed  Google Scholar 

  92. Dugan CM, MacDonald AE, Roth RA, Ganey PE (2010) A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther 333:364–372

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Efe C (2013) Drug induced autoimmune hepatitis and TNF-alpha blocking agents: is there a real relationship? Autoimmun Rev 12:337–339

    CAS  PubMed  Google Scholar 

  94. Efe C, Heurgue-Berlot A, Ozaslan E, Purnak T, Thiefin G, Simsek H, Wahlin S (2013) Late autoimmune hepatitis after hepatitis C therapy. Eur J Gastroenterol Hepatol 25:1308–1311

    CAS  PubMed  Google Scholar 

  95. Eliasson E, Gardner I, Hume-Smith H, de Waziers I, Beaune P, Kenna JG (1998) Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis. Chem Biol Interact 116:123–141

    CAS  PubMed  Google Scholar 

  96. Elkayam O, Yaron M, Caspi D (1999) Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 28:392–397

    CAS  PubMed  Google Scholar 

  97. Erlinger S (1997) Drug-induced cholestasis. J Hepatol 26(Suppl 1):1–4

    CAS  PubMed  Google Scholar 

  98. Ersoz G, Vardar R, Akarca US, Tekin F, Yilmaz F, Gunsar F, Karasu Z (2011) Ornidazole-induced autoimmune hepatitis. Turk J Gastroenterol 22:494–499

    PubMed  Google Scholar 

  99. Fairhurst DA, Sheehan-Dare R (2009) Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis. Clin Exp Dermatol 34:421–422

    CAS  PubMed  Google Scholar 

  100. Fan CQ, Crawford JM (2014) Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol 4:332–346

    PubMed  PubMed Central  Google Scholar 

  101. Farrell GC (1994) Drug-induced liver disease. Churchill Livingstone, Edinburgh

    Google Scholar 

  102. Farrell GC (1994) Drug-induced steatohepatitis. In: Farrell GC (Hrsg) Drug-Induced liver disease. Edinburgh, Churchill Livingstone, S 431–438

    Google Scholar 

  103. Farrell GC (2000) Drugs and non-alcoholic steatohepatitis. In: Leuschner U, James O, Dancygier H (Hrsg) Falk Symposium 121 – Steatohepatitis (NASH and ASH), Bd. 121. Kluwer, Dordrecht

    Google Scholar 

  104. Farrell GC (2002) Drugs and steatohepatitis. Semin Liver Dis 22:185–194

    CAS  PubMed  Google Scholar 

  105. Fathalla BM, Goldsmith DP, Pascasio JM, Baldridge A (2008) Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept. J Clin Rheumatol 14:297–298

    PubMed  Google Scholar 

  106. Fedotin MS, Lefer LG (1975) Liver disease caused by propylthiouracil. Arch Intern Med 135:319–321

    CAS  PubMed  Google Scholar 

  107. Fidler H, Dhillon A, Gertner D, Burroughs A (1996) Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol 25:563–566

    CAS  PubMed  Google Scholar 

  108. Fontana RJ, Seeff LB, Andrade RJ, Bjornsson E, Day CP, Serrano J, Hoofnagle JH (2010) Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 52:730–742

    PubMed  PubMed Central  Google Scholar 

  109. Forbes GM, Jeffrey GP, Shilkin KB, Reed WD (1992) Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 102:1385–1388

    CAS  PubMed  Google Scholar 

  110. Ford TJ, Dillon JF (2008) Minocycline hepatitis. Eur J Gastroenterol Hepatol 20:796–799

    CAS  PubMed  Google Scholar 

  111. Fountain FF, Tolley E, Chrisman CR, Self TH (2005) Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 128:116–123

    CAS  PubMed  Google Scholar 

  112. Fromenty B, Pessayre D (1995) Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 67:101–154

    CAS  PubMed  Google Scholar 

  113. Gebhardt R (1992) Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol Ther 53:275–354

    CAS  PubMed  Google Scholar 

  114. Geier A, Wagner M, Dietrich CG, Trauner M (2007) Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 1773:283–308

    CAS  PubMed  Google Scholar 

  115. Gentilucci UV, Santini D, Vincenzi B, Fiori E, Picardi A, Tonini G (2006) Chemotherapy-induced steatohepatitis in colorectal cancer patients. J Clin Oncol 24:5467 (author reply 5467–5468)

    PubMed  Google Scholar 

  116. Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, Valesini G (2005) Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 64:1519–1520

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C (1991) Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 100:1701–1709

    CAS  PubMed  Google Scholar 

  118. Giannattasio A, D’Ambrosi M, Volpicelli M, Iorio R (2006) Steroid therapy for a case of severe drug-induced cholestasis. Ann Pharmacother 40:1196–1199

    PubMed  Google Scholar 

  119. Gilbert KM, Przybyla B, Pumford NR, Han T, Fuscoe J, Schnackenberg LK, Holland RD et al (2009) Delineating liver events in trichloroethylene-induced autoimmune hepatitis. Chem Res Toxicol 22:626–632

    CAS  PubMed  Google Scholar 

  120. Gilbert SC, Klintmalm G, Menter A, Silverman A (1990) Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this “steroid-sparing” agent. Arch Intern Med 150:889–891

    CAS  PubMed  Google Scholar 

  121. Goldstein LI, Granoff M, Waisman J (1978) Hepatic injury due to oxacillin administration. Am J Gastroenterol 70:171–174

    CAS  PubMed  Google Scholar 

  122. Goldstein NS, Bayati N, Silverman AL, Gordon SC (2000) Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 114:591–598

    CAS  PubMed  Google Scholar 

  123. Golstein PE, Deviere J, Cremer M (1997) Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 92:143–146

    CAS  PubMed  Google Scholar 

  124. Goodman ZD (2002) Drug hepatotoxicity. Clin Liver Dis 6:381–397

    PubMed  Google Scholar 

  125. Gough A, Chapman S, Wagstaff K, Emery P, Elias E (1996) Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 312:169–172

    CAS  PubMed  PubMed Central  Google Scholar 

  126. Gradon JD, Sepkowitz DV (1990) Massive hepatic enlargement with fatty change associated with ketoconazole. DICP 24:1175–1176

    CAS  PubMed  Google Scholar 

  127. Grattagliano I, Ubaldi E, Bonfrate L, Portincasa P (2011) Management of liver cirrhosis between primary care and specialists. World J Gastroenterol 17:2273–2282

    PubMed  PubMed Central  Google Scholar 

  128. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W (2003) Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12:409–412

    CAS  PubMed  Google Scholar 

  129. Grieco A, Alfei B, Di Rocco P, Miele L, Biolcati G, Griso D, Vecchio FM et al (2001) Non-alcoholic steatohepatitis induced by carbamazepine and variegate porphyria. Eur J Gastroenterol Hepatol 13:973–975

    CAS  PubMed  Google Scholar 

  130. Gu X, Manautou JE (2012) Molecular mechanisms underlying chemical liver injury. Expert Rev Mol Med 14:e4

    PubMed  PubMed Central  Google Scholar 

  131. Guzman G, Kallwitz ER, Wojewoda C, Chennuri R, Berkes J, Layden TJ, Cotler SJ (2009) Liver injury with features mimicking autoimmune hepatitis following the use of black cohosh. Case Rep Med 2009:918156

    PubMed  Google Scholar 

  132. Haboubi NY, Ali HH, Whitwell HL, Ackrill P (1988) Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: light microscopy and ultrastructural observations. Am J Gastroenterol 83:256–261

    CAS  PubMed  Google Scholar 

  133. Hackstein H, Mohl W, Puschel W, Stallmach A, Zeitz M (1998) Diclofenac-associated acute cholestatis hepatitis. Z Gastroenterol 36:385–389

    CAS  PubMed  Google Scholar 

  134. Hamada N, Ogawa Y, Saibara T, Murata Y, Kariya S, Nishioka A, Terashima M et al (2000) Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Int J Oncol 17:1119–1123

    CAS  PubMed  Google Scholar 

  135. Han D, Shinohara M, Ybanez MD, Saberi B, Kaplowitz N (2010) Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol 196:267–310

    CAS  Google Scholar 

  136. Harada K, Akai Y, Koyama S, Ikenaka Y, Saito Y (2008) A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. Clin Rheumatol 27:1063–1066

    PubMed  Google Scholar 

  137. Harb R, Xie G, Lutzko C, Guo Y, Wang X, Hill CK, Kanel GC et al (2009) Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology 137:704–712

    PubMed  PubMed Central  Google Scholar 

  138. Hatoff DE, Cohen M, Schweigert BF, Talbert WM (1979) Nitrofurantoin: another cause of drug-induced chronic active hepatitis? A report of a patient with HLA-B8 antigen. Am J Med 67:117–121

    CAS  PubMed  Google Scholar 

  139. Hautekeete ML, Kockx MM, Naegels S, Holvoet JK, Hubens H, Kloppel G (1995) Cholestatic hepatitis related to quinolones: a report of two cases. J Hepatol 23:759–760

    CAS  PubMed  Google Scholar 

  140. Heidelbauch JJ, Sherbondy M (2006) Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. www.aafp.org/afp

  141. Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J (1990) Diclofenac-associated hepatotoxicity. JAMA 264:2660–2662

    CAS  PubMed  Google Scholar 

  142. Helmy A (2006) Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther 23:11–25

    CAS  PubMed  Google Scholar 

  143. Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS (2013) Autoimmune hepatitis. Lancet 382:1433–1444

    CAS  PubMed  Google Scholar 

  144. Herzog D, Hajoui O, Russo P, Alvarez F (1997) Study of immune reactivity of minocycline-induced chronic active hepatitis. Dig Dis Sci 42:1100–1103

    CAS  PubMed  Google Scholar 

  145. Hinrichsen H, Luttges J, Kloppel G, Folsch UR, Schmidt WE (2001) Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. Scand J Gastroenterol 36:780–783

    CAS  PubMed  Google Scholar 

  146. Holt M, Ju C (2010) Drug-induced liver injury. Handb Exp Pharmacol 196:3–27

    CAS  Google Scholar 

  147. Homberg JC, Abuaf N, Helmy-Khalil S, Biour M, Poupon R, Islam S, Darnis F et al (1985) Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology 5:722–727

    CAS  PubMed  Google Scholar 

  148. Homberg JC, Andre C, Abuaf N (1984) A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 55:561–570

    CAS  PubMed  PubMed Central  Google Scholar 

  149. Horst DA, Grace ND, LeCompte PM (1980) Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology 79:550–554

    CAS  PubMed  Google Scholar 

  150. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY et al (2003) Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924–930

    CAS  PubMed  Google Scholar 

  151. Humayun F, Shehab TM, Tworek JA, Fontana RJ (2007) A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report. J Med Case Rep 1:88

    PubMed  PubMed Central  Google Scholar 

  152. Hutter RV, Shipkey FH, Tan CT, Murphy ML, Chowdhury M (1960) Hepatic fibrosis in children with acute leukemia: a complication of therapy. Cancer 13:288–307

    CAS  PubMed  Google Scholar 

  153. Hytiroglou P, Tobias H, Saxena R, Abramidou M, Papadimitriou CS, Theise ND (2004) The canals of hering might represent a target of methotrexate hepatic toxicity. Am J Clin Pathol 121:324–329

    CAS  PubMed  Google Scholar 

  154. Inno A, Basso M, Vecchio FM, Marsico VA, Cerchiaro E, D’Argento E, Bagala C et al (2011) Anastrozole-related acute hepatitis with autoimmune features: a case report. BMC Gastroenterol 11:32

    PubMed  PubMed Central  Google Scholar 

  155. Ishak KG (1982) The Liver. In: Riddell RH (Hrsg) Pathology of drug-induced and toxic diseases. Churchill Livingstone, New York, S 457–513

    Google Scholar 

  156. Ishak KG, Zimmerman HJ (1995) Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 24:759–786

    CAS  PubMed  Google Scholar 

  157. Islam S, Mekhloufi F, Paul JM, Islam M, Johanet C, Legendre C, Degott C et al (1989) Characteristics of clometacin-induced hepatitis with special reference to the presence of anti-actin cable antibodies. Autoimmunity 2:213–221

    CAS  PubMed  Google Scholar 

  158. Isoard B, Daumont M, Pousset G, Paliard P (1988) Pseudoalcoholic hepatitis during treatment with nicardipine. Presse Med 17:647–648

    CAS  PubMed  Google Scholar 

  159. Jacques EA, Buschmann RJ, Layden TJ (1979) The histopathologic progression of vitamin A-induced hepatic injury. Gastroenterology 76:599–602

    CAS  PubMed  Google Scholar 

  160. Jaeschke H, Knight TR, Bajt ML (2003) The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol Lett 144:279–288

    CAS  PubMed  Google Scholar 

  161. Jones BE, Lo CR, Liu H, Srinivasan A, Streetz K, Valentino KL, Czaja MJ (2000) Hepatocytes sensitized to tumor necrosis factor-alpha cytotoxicity undergo apoptosis through caspase-dependent and caspase-independent pathways. J Biol Chem 275:705–712

    CAS  PubMed  Google Scholar 

  162. Jorens PG, Michielsen PP, Pelckmans PA, Fevery J, Desmet VJ, Geubel AP, Rahier J et al (1992) Vitamin A abuse: development of cirrhosis despite cessation of vitamin A. A six-year clinical and histopathologic follow-up. Liver 12:381–386

    CAS  PubMed  Google Scholar 

  163. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, Sasaki T et al (2001) Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410:549–554

    CAS  PubMed  Google Scholar 

  164. Jungermann K, Kietzmann T (1996) Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr 16:179–203

    CAS  PubMed  Google Scholar 

  165. Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685–708

    CAS  PubMed  Google Scholar 

  166. Kamiyama T, Nouchi T, Kojima S, Murata N, Ikeda T, Sato C (1997) Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroenterol 92:703–704

    CAS  PubMed  Google Scholar 

  167. Kancherla D, Gajendran M, Vallabhaneni P, Vipperla K (2013) Metronidazole induced liver injury: a rare immune mediated drug reaction. Case Rep Gastrointest Med 2013:568193

    PubMed  PubMed Central  Google Scholar 

  168. Kanel GC (2007) Histopathology of drug-induced liver disease. In: Kaplowitz N, DeLeve LD (Hrsg) Drug-induced liver disease, 2. Aufl. Informa Healthcare, New York, S 237–289

    Google Scholar 

  169. Kaplowitz N, DeLeve LD (Hrsg) (2007) Drug-induced liver disease. Informa Healthcare, New York

    Google Scholar 

  170. Karthik SV, Casson D (2005) Erythromycin-associated cholestatic hepatitis and liver dysfunction in children: the British experience. J Clin Gastroenterol 39:743–744

    PubMed  Google Scholar 

  171. Kass GE, Price SC (2008) Role of mitochondria in drug-induced cholestatic injury. Clin Liver Dis 12:27–51

    PubMed  Google Scholar 

  172. Kern E, VanWagner LB, Yang GY, Rinella ME (2014) Liraglutide-induced autoimmune hepatitis. JAMA Intern Med 174:984–987

    CAS  PubMed  PubMed Central  Google Scholar 

  173. Kessler WR, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY (2004) Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2:625–631

    PubMed  Google Scholar 

  174. Kew MC (2000) Serum aminotransferase concentration as evidence of hepatocellular damage. Lancet 355:591–592

    CAS  PubMed  Google Scholar 

  175. Khakoo SI, Coles CJ, Armstrong JS, Barry RE (1995) Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine (“ecstasy”) usage. J Clin Gastroenterol 20:244–247

    CAS  PubMed  Google Scholar 

  176. Khokhar O, Gange C, Clement S, Lewis J (2005) Autoimmune hepatitis and thyroiditis associated with rifampin and pyrazinamide prophylaxis: an unusual reaction. Dig Dis Sci 50:207–211

    PubMed  Google Scholar 

  177. Khouri MR, Saul SH, Dlugosz AA, Soloway RD (1987) Hepatocanalicular injury associated with vitamin A derivative etretinate. An idiosyncratic hypersensitivity reaction. Dig Dis Sci 32:1207–1211

    CAS  PubMed  Google Scholar 

  178. Kimbrough RD (1987) Human health effects of polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs). Annu Rev Pharmacol Toxicol 27:87–111

    CAS  PubMed  Google Scholar 

  179. Kleiner DE (2009) The pathology of drug-induced liver injury. Semin Liver Dis 29:364–372

    PubMed  Google Scholar 

  180. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313–1321

    PubMed  Google Scholar 

  181. Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB, Hayashi PH et al (2014) Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59:661–670

    PubMed  Google Scholar 

  182. Knowles SR, Shapiro L, Shear NH (1996) Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 132:934–939

    CAS  PubMed  Google Scholar 

  183. Kochar R, Nevah MI, Lukens FJ, Fallon MB, Machicao VI (2010) Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited. World J Gastroenterol 16:3335–3338

    PubMed  PubMed Central  Google Scholar 

  184. Kosar Y, Sasmaz N, Oguz P, Kacar S, Erden E, Parlak E, Akdogan M (2001) Ornidazole-induced autoimmune hepatitis. Eur J Gastroenterol Hepatol 13:737–739

    CAS  PubMed  Google Scholar 

  185. Kosters A, Karpen SJ (2010) The role of inflammation in cholestasis: clinical and basic aspects. Semin Liver Dis 30:186–194

    CAS  PubMed  PubMed Central  Google Scholar 

  186. Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, Calmy A et al (2009) Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 49:626–635

    CAS  PubMed  Google Scholar 

  187. Kowalski TE, Falestiny M, Furth E, Malet PF (1994) Vitamin A hepatotoxicity: a cautionary note regarding 25,000 IU supplements. Am J Med 97:523–528

    CAS  PubMed  Google Scholar 

  188. Krähenbühl S, Kaplowitz N (1996) Drug-induced hepatotoxicity: clinical presentation. pathogenesis, risk factors, diagnosis and treatment. In: Schmid R, Bianchi L, Blum HE, Gerok W, Maier KP, Stalder GA (Hrsg) Acute and chronic liver diseases molecular biology and clinics. Kluwer, Dordrecht, S 147–158

    Google Scholar 

  189. Krebs S, Dormann H, Muth-Selbach U, Hahn EG, Brune K, Schneider HT (2001) Risperidone-induced cholestatic hepatitis. Eur J Gastroenterol Hepatol 13:67–69

    CAS  PubMed  Google Scholar 

  190. Kremer JM, Lee RG, Tolman KG (1989) Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 32:121–127

    CAS  PubMed  Google Scholar 

  191. Lai KK, Gang DL, Zawacki JK, Cooley TP (1991) Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddI). Ann Intern Med 115:283–284

    CAS  PubMed  Google Scholar 

  192. Langman G, Hall PM, Todd G (2001) Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 16:1395–1401

    CAS  PubMed  Google Scholar 

  193. Larrey D (2002) Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 22:145–155

    CAS  PubMed  Google Scholar 

  194. Larrey D, Vial T, Pauwels A, Castot A, Biour M, David M, Michel H (1992) Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 117:129–132

    CAS  PubMed  Google Scholar 

  195. Lawrence SP (1993) Transient focal hepatic defects related to sustained-release niacin. J Clin Gastroenterol 16:234–236

    CAS  PubMed  Google Scholar 

  196. Lecoeur S, Andre C, Beaune PH (1996) Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 50:326–333

    CAS  PubMed  Google Scholar 

  197. Lehmann-McKeeman LD (2008) Absorption, distribution, and excretion of toxicants. In: Casarett LJ, Doull J (Hrsg) Casarett and Doull’s toxicology: the basic science of poisons, 7. Aufl. McGraw-Hill, New York, S 131–159

    Google Scholar 

  198. Leithead JA, Simpson KJ, MacGilchrist AJ (2009) Fulminant hepatic failure following overdose of the vitamin A metabolite acitretin. Eur J Gastroenterol Hepatol 21:230–232

    CAS  PubMed  Google Scholar 

  199. Leo MA, Lieber CS (1988) Hypervitaminosis A: a liver lover’s lament. Hepatology 8:412–417

    CAS  PubMed  Google Scholar 

  200. Lewis JH, Kleiner D (2012) Hepatic injury due to drugs, herbal compounds, chemicals and toxins. In: MacSween RNM, Burt AD, Portmann BC (Hrsg) MacSween Pathology of the Liver, 6. Aufl. Elsevier, Amsterdam, S 645–760

    Google Scholar 

  201. Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse RM, Rusnock EJ et al (1990) Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 21:59–67

    CAS  PubMed  Google Scholar 

  202. Lewis JH, Schiff E (1988) Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol 83:1337–1345

    CAS  PubMed  Google Scholar 

  203. Lewis JH, Zimmerman HJ (1998) Drug-induced autoimmune liver disease. In: Krawitt EL, Wiesner RH, Nishioka K (Hrsg) Autoimmune liver diseases, 2. Aufl. Elsevier, Amsterdam, S 627–649

    Google Scholar 

  204. Lewis JJ, Iezzoni JC, Berg CL (2007) Methylphenidate-induced autoimmune hepatitis. Dig Dis Sci 52:594–597

    PubMed  Google Scholar 

  205. Li MK, Crawford JM (2004) The pathology of cholestasis. Semin Liver Dis 24:21–42

    PubMed  Google Scholar 

  206. Lim JR, Faught PR, Chalasani NP, Molleston JP (2006) Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 148:831–834

    PubMed  Google Scholar 

  207. Lindberg MC (1992) Hepatobiliary complications of oral contraceptives. J Gen Intern Med 7:199–209

    CAS  PubMed  Google Scholar 

  208. Lionte C (2010) Lethal complications after poisoning with chloroform – case report and literature review. Hum Exp Toxicol 29:615–622

    CAS  PubMed  Google Scholar 

  209. Lisotti A, Azzaroli F, Brillanti S, Mazzella G (2012) Severe acute autoimmune hepatitis after natalizumab treatment. Dig Liver Dis 44:356–357

    PubMed  Google Scholar 

  210. Liu ZX, Kaplowitz N (2002) Immune-mediated drug-induced liver disease. Clin Liver Dis 6:755–774

    PubMed  Google Scholar 

  211. Lockwood AM, Cole S, Rabinovich M (2010) Azithromycin-induced liver injury. Am J Health Syst Pharm 67:810–814

    CAS  PubMed  Google Scholar 

  212. Lu J, Jones AD, Harkema JR, Roth RA, Ganey PE (2012) Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci 125:126–133

    CAS  PubMed  Google Scholar 

  213. Lucena MI, Andrade RJ, Fernandez MC, Pachkoria K, Pelaez G, Duran JA, Villar M et al (2006) Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 44:850–856

    CAS  PubMed  Google Scholar 

  214. Lucena MI, Garcia-Martin E, Andrade RJ, Martinez C, Stephens C, Ruiz JD, Ulzurrun E et al (2010) Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 52:303–312

    CAS  PubMed  Google Scholar 

  215. Ludwig J, Axelsen R (1983) Drug effects on the liver. An updated tabular compilation of drugs and drug-related hepatic diseases. Dig Dis Sci 28:651–666

    CAS  PubMed  Google Scholar 

  216. Lullmann H, Lullmann-Rauch R, Wassermann O (1975) Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit Rev Toxicol 4:185–218

    CAS  PubMed  Google Scholar 

  217. Maggiore G, Larizza D, Lorini R, De Giacomo C, Scotta MS, Severi F (1989) Propylthiouracil hepatotoxicity mimicking autoimmune chronic active hepatitis in a girl. J Pediatr Gastroenterol Nutr 8:547–548

    CAS  PubMed  Google Scholar 

  218. Manier JW, Chang WW, Kirchner JP, Beltaos E (1982) Hepatotoxicity associated with ticrynafen – a uricosuric diuretic. Am J Gastroenterol 77:401–404

    CAS  PubMed  Google Scholar 

  219. Manivel JC, Bloomer JR, Snover DC (1987) Progressive bile duct injury after thiabendazole administration. Gastroenterology 93:245–249

    CAS  PubMed  Google Scholar 

  220. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM et al (2010) Diagnosis and management of autoimmune hepatitis. Hepatology 51:2193–2213

    CAS  PubMed  Google Scholar 

  221. Marques M, Magro F, Cardoso H, Carneiro F, Portugal R, Lopes J, Costa Santos C (2008) Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 14:723–725

    CAS  PubMed  Google Scholar 

  222. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14:72–81

    CAS  PubMed  Google Scholar 

  223. Martinez-Lapiscina EH, Lacruz F, Bolado-Concejo F, Rodriguez-Perez I, Ayuso T, Garaigorta M, Urman JM (2013) Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis. Mult Scler 19:1234–1235

    CAS  PubMed  Google Scholar 

  224. Martinez-Odriozola P, Gutierrez-Macias A, Ibarmia-Lahuerta J, Munoz-Sanchez J (2010) Meloxicam as a cause of drug-induced autoimmune hepatitis. Dig Dis Sci 55:1191–1192

    PubMed  Google Scholar 

  225. Maruyama S, Hirayama C, Abe J, Tanaka J, Matsui K (1995) Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy. Dig Dis Sci 40:2602–2607

    CAS  PubMed  Google Scholar 

  226. Mason RP, Chignell CF (1981) Free radicals in pharmacology and toxicology – selected topics. Pharmacol Rev 33:189–211

    CAS  PubMed  Google Scholar 

  227. Mendler MH, Kanel G, Govindarajan S (2005) Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int 25:294–304

    PubMed  Google Scholar 

  228. Misdraji J (2010) Embryology, anatomy, histology, and developmental anomalies of the liver. In: Sleisenger MH, Feldman M (Hrsg) Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management, 9. Aufl. Saunders, Philadelphia, S 1201–1206

    Google Scholar 

  229. Mizutani T, Shinoda M, Tanaka Y, Kuno T, Hattori A, Usui T, Kuno N et al (2005) Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab Rev 37:235–252

    CAS  PubMed  Google Scholar 

  230. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost R, Schmid M (1994) Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 20:1437–1441

    CAS  PubMed  Google Scholar 

  231. Morii K, Nishisaka M, Nakamura S, Oda T, Aoyama Y, Yamamoto T, Kishida H et al (2014) A case of synthetic oestrogen-induced autoimmune hepatitis with microvesicular steatosis. J Clin Pharm Ther 39:573–576

    CAS  PubMed  Google Scholar 

  232. Nadir A, Agrawal S, King PD, Marshall JB (1996) Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol 91:1436–1438

    CAS  PubMed  Google Scholar 

  233. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ et al (2003) Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 63:732–741

    CAS  PubMed  Google Scholar 

  234. Naito A, Terada J, Tanabe N, Sugiura T, Sakao S, Kanda T, Yokosuka O et al (2014) Autoimmune hepatitis in a patient with pulmonary arterial hypertension treated with endothelin receptor antagonists. Intern Med 53:771–775

    PubMed  Google Scholar 

  235. Nakanishi Y, Saxena R (2015) Pathophysiology and diseases of the proximal pathways of the biliary system. Arch Pathol Lab Med 139:858–866

    CAS  PubMed  Google Scholar 

  236. Navarro VJ, Lucena MI (2014) Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis 34:172–193

    CAS  PubMed  Google Scholar 

  237. Nelson SD (1990) Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin Liver Dis 10:267–278

    CAS  PubMed  Google Scholar 

  238. Nemeth E, Baird AW, O’Farrelly C (2009) Microanatomy of the liver immune system. Semin Immunopathol 31:333–343

    PubMed  Google Scholar 

  239. Neuberger J, Kenna JG (1987) Halothane hepatitis: a model of immune mediated drug hepatotoxicity. Clin Sci (Lond) 72:263–270

    CAS  Google Scholar 

  240. Nietsch HH, Libman BS, Pansze TW, Eicher JN, Reeves JR, Krawitt EL (2000) Minocycline-induced hepatitis. Am J Gastroenterol 95:2993–2995

    CAS  PubMed  Google Scholar 

  241. Njoku DB (2014) Drug-induced hepatotoxicity: metabolic, genetic and immunological basis. Int J Mol Sci 15:6990–7003

    CAS  PubMed  PubMed Central  Google Scholar 

  242. Ogilvie BW (2008) Biotransformation of xenobiotics. In: Casarett LJ, Doull J (Hrsg) Casarett and Doull’s toxicology: the basic science of poisons, 7. Aufl. McGraw-Hill, New York, S 161–304

    Google Scholar 

  243. Oien KA, Moffat D, Curry GW, Dickson J, Habeshaw T, Mills PR, MacSween RN (1999) Cirrhosis with steatohepatitis after adjuvant tamoxifen. Lancet 353:36–37

    CAS  PubMed  Google Scholar 

  244. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M (1992) Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 15:154–161

    CAS  PubMed  Google Scholar 

  245. Oneta CM, Dufour JF (2003) Diagnostik, Prognose und therapeutische Möglichkeiten der nicht-alkoholischen Fettlebererkrankung. Swiss Med Forum 37:862–868

    Google Scholar 

  246. Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C (2007) Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 187:524–526

    PubMed  Google Scholar 

  247. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK (1996) Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 51:132–136

    CAS  PubMed  PubMed Central  Google Scholar 

  248. Paredes AH, Lewis JH (2007) Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection. Ann Pharmacother 41:880–884

    CAS  PubMed  Google Scholar 

  249. Pariente EA, Hamoud A, Goldfain D, Latrive JP, Gislon J, Cassan P, Morin T et al (1989) Hepatitis caused by clometacin (Duperan). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis? Gastroenterol Clin Biol 13:769–774

    CAS  PubMed  Google Scholar 

  250. Patel V, Sanyal AJ (2013) Drug-induced steatohepatitis. Clin Liver Dis 17:533–546

    PubMed  PubMed Central  Google Scholar 

  251. Pauli-Magnus C, Meier PJ (2006) Hepatobiliary transporters and drug-induced cholestasis. Hepatology 44:778–787

    CAS  PubMed  Google Scholar 

  252. Peevers CG, Moorghen M, Collins PL, Gordon FH, McCune CA (2010) Liver disease and cirrhosis because of Khat chewing in UK Somali men: a case series. Liver Int 30:1242–1243

    PubMed  Google Scholar 

  253. Pessayre D, Berson A, Fromenty B, Mansouri A (2001) Mitochondria in steatohepatitis. Semin Liver Dis 21:57–69

    CAS  PubMed  Google Scholar 

  254. Pessayre D, Degos F, Feldmann G, Degott C, Bernuau J, Benhamou JP (1981) Chronic active hepatitis and giant multinucleated hepatocytes in adults treated with clometacin. Digestion 22:66–72

    CAS  PubMed  Google Scholar 

  255. Picciotto A, Campo N, Brizzolara R, Giusto R, Guido G, Sinelli N, Lapertosa G et al (1998) Chronic hepatitis induced by Jin Bu Huan. J Hepatol 28:165–167

    CAS  PubMed  Google Scholar 

  256. Pichler WJ (2005) Direct T-cell stimulations by drugs – bypassing the innate immune system. Toxicology 209:95–100

    CAS  PubMed  Google Scholar 

  257. Pieterse AS, Rowland R, Dunn D (1983) Perhexiline maleate induced cirrhosis. Pathology 15:201–203

    CAS  PubMed  Google Scholar 

  258. Pineda JA, Larrauri J, Macias J, Hernandez A, Guijarro J, Sayago M, Gavilan F et al (1999) Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine. J Hepatol 31:777–778

    CAS  PubMed  Google Scholar 

  259. Pirovino M, Müller O, Zysset T, Honegger U (1988) Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model. Hepatology 8:591–598

    CAS  PubMed  Google Scholar 

  260. Pohl LR, Satoh H, Christ DD, Kenna JG (1988) The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol 28:367–387

    CAS  PubMed  Google Scholar 

  261. Polson JE (2007) Hepatotoxicity due to antibiotics. Clin Liver Dis 11:549–561

    PubMed  Google Scholar 

  262. Poncin E, Silvain C, Touchard G, Barbier J, Beauchant M (1986) Papaverine-induced chronic liver disease. Gastroenterology 90:1051–1053

    CAS  PubMed  Google Scholar 

  263. Primo J, Michavila J, Jimenez I (2010) Efalizumab-induced autoimmune hepatitis. Gastroenterol Hepatol 33:69–70

    PubMed  Google Scholar 

  264. Raja K, Thung SN, Fiel MI, Chang C (2009) Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis 29:423–428

    CAS  PubMed  Google Scholar 

  265. Ramachandran R, Kakar S (2009) Histological patterns in drug-induced liver disease. J Clin Pathol 62:481–492

    CAS  PubMed  Google Scholar 

  266. Rao MS, Reddy JK (2001) Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 21:43–55

    CAS  PubMed  Google Scholar 

  267. Reynolds JD, Wilber RD (1972) Chronic active hepatitis associated with oxyphenisatin. Am J Gastroenterol 57:566–570

    CAS  PubMed  Google Scholar 

  268. Reynolds TB, Peters RL, Yamada S (1971) Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin. N Engl J Med 285:813–820

    CAS  PubMed  Google Scholar 

  269. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP (1991) Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 49:13–17

    CAS  PubMed  Google Scholar 

  270. Robin MA, Le Roy M, Descatoire V, Pessayre D (1997) Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 26(Suppl 1):23–30

    CAS  PubMed  Google Scholar 

  271. Roda G, Caponi A, Belluzzi A, Roda E (2009) Severe cholestatic acute hepatitis following azathioprine therapy in a patient with ulcerative pancolitis. Dig Liver Dis 41:914–915

    CAS  PubMed  Google Scholar 

  272. Rodman JS, Deutsch DJ, Gutman SI (1976) Methyldopa Hepatitis. A report of six cases and review of the literature. Am J Med 60:941–948

    CAS  PubMed  Google Scholar 

  273. Roenigk HH Jr., Auerbach R, Maibach H, Weinstein G, Lebwohl M (1998) Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 38:478–485

    PubMed  Google Scholar 

  274. Roenigk HH Jr., Auerbach R, Maibach HI, Weinstein GD (1988) Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 19:145–156

    PubMed  Google Scholar 

  275. Romagnuolo J, Sadowski DC, Lalor E, Jewell L, Thomson AB (1998) Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 12:479–483

    CAS  PubMed  Google Scholar 

  276. Roy AK, Mahoney HC, Levine RA (1993) Phenytoin-induced chronic hepatitis. Dig Dis Sci 38:740–743

    CAS  PubMed  Google Scholar 

  277. Roy MA, Nugent FW, Aretz HT (1989) Micronodular cirrhosis after thiabendazole. Dig Dis Sci 34:938–941

    CAS  PubMed  Google Scholar 

  278. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460–466

    CAS  PubMed  Google Scholar 

  279. Russmann S, Lauterburg BH (2002) Medikamentös-toxische Leberschäden. Schweiz Med Forum 44:1044–1070

    Google Scholar 

  280. Russo MW, Scobey M, Bonkovsky HL (2009) Drug-induced liver injury associated with statins. Semin Liver Dis 29:412–422

    CAS  PubMed  Google Scholar 

  281. Saad EI, El-Gowilly SM, Sherhaa MO, Bistawroos AE (2010) Role of oxidative stress and nitric oxide in the protective effects of alpha-lipoic acid and aminoguanidine against isoniazid-rifampicin-induced hepatotoxicity in rats. Food Chem Toxicol 48:1869–1875

    CAS  PubMed  Google Scholar 

  282. Schweitzer IL, Peters RL (1974) Acute submassive hepatic necrosis due to methyldopa. A case demonstrating possible initiation of chronic liver disease. Gastroenterology 66:1203–1211

    CAS  PubMed  Google Scholar 

  283. Scully LJ, Clarke D, Barr RJ (1993) Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 38:744–751

    CAS  PubMed  Google Scholar 

  284. Seidel C, Fenner M, Langer F, Bantel H, Ganser A, Grunwald V (2012) Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). BMC Cancer 12:186

    CAS  PubMed  PubMed Central  Google Scholar 

  285. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C et al (2002) Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36:451–455

    PubMed  Google Scholar 

  286. Shalev O, Mosseri M, Ariel I, Stalnikowicz R (1983) Methyldopa-induced immune hemolytic anemia and chronic active hepatitis. Arch Intern Med 143:592–593

    CAS  PubMed  Google Scholar 

  287. Sharp JR, Ishak KG, Zimmerman HJ (1980) Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 92:14–19

    CAS  PubMed  Google Scholar 

  288. Sheikh NM, Philen RM, Love LA (1997) Chaparral-associated hepatotoxicity. Arch Intern Med 157:913–919

    CAS  PubMed  Google Scholar 

  289. Sherigar JM, Fazio R, Zuang M, Arsura E (2012) Autoimmune hepatitis induced by nitrofurantoin. The importance of the autoantibodies for an early diagnosis of immune disease. Clin Pract 2:e83

    PubMed  PubMed Central  Google Scholar 

  290. Shikata T, Oda T, Naito C, Kanetaka T, Suzuki H (1970) Phospholipid fatty liver: a proposal of a new concept and its electron microscopical study. Acta Pathol Jpn 20:467–486

    CAS  PubMed  Google Scholar 

  291. Silva MF, Ruiter JP, Illst L, Jakobs C, Duran M, de Almeida IT, Wanders RJ (1997) Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro. J Inherit Metab Dis 20:397–400

    CAS  PubMed  Google Scholar 

  292. Sirichindakul B, Sriuranpong V, Wisedopas N, Nonthasoot B, Suphapol J, Nivatvongs S (2011) Imatinib-induced subclinical liver injury: histological changes of non-tumorous hepatic parenchyma. Asian Biomed (Res Rev News) 5:837–841

    CAS  Google Scholar 

  293. Skoog SM, Smyrk TC, Talwalkar JA (2004) Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol 38:833

    PubMed  Google Scholar 

  294. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, Krishnamoorthy R (2004) Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104:1574–1577

    CAS  PubMed  Google Scholar 

  295. Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH (2010) Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 52:258–271

    CAS  PubMed  Google Scholar 

  296. Sterling MJ, Kane M, Grace ND (1996) Pemoline-induced autoimmune hepatitis. Am J Gastroenterol 91:2233–2234

    CAS  PubMed  Google Scholar 

  297. Stickel F, Patsenker E, Schuppan D (2005) Herbal hepatotoxicity. J Hepatol 43:901–910

    PubMed  Google Scholar 

  298. Stravitz RT, Sanyal AJ (2003) Drug-induced steatohepatitis. Clin Liver Dis 7:435–451

    PubMed  Google Scholar 

  299. Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ (1988) Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 8:599–606

    CAS  PubMed  Google Scholar 

  300. Sugimoto K, Ito T, Yamamoto N, Shiraki K (2011) Seven cases of autoimmune hepatitis that developed after drug-induced liver injury. Hepatology 54:1892–1893

    PubMed  Google Scholar 

  301. Suk KT, Kim DJ, Kim CH, Park SH, Yoon JH, Kim YS, Baik GH et al (2012) A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 107:1380–1387

    PubMed  Google Scholar 

  302. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, Lucena MI et al (2011) The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 54:931–939

    PubMed  PubMed Central  Google Scholar 

  303. Takegoshi T, Tohyama T, Cox D (1996) Hepatotoxicity associated with herbal tablets (letter). Brit Med J 313:92

    Google Scholar 

  304. Tallman MS, McDonald GB, DeLeve LD, Baer MR, Cook MN, Graepel GJ, Kollmer C (2013) Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice. Int J Hematol 97:456–464

    PubMed  Google Scholar 

  305. Taylor AE, Mitchison H (1991) Fatty liver following isotretinoin therapy. Br J Dermatol 124:505–506

    CAS  PubMed  Google Scholar 

  306. Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM (1998) Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med 152:1132–1136

    CAS  PubMed  Google Scholar 

  307. Temple R (2006) Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15:241–243

    PubMed  Google Scholar 

  308. ter Borg EJ, Seldenrijk CA, Timmer R (1996) Liver cirrhosis due to methotrexate in a patient with rheumatoid arthritis. Neth J Med 49:244–246

    PubMed  Google Scholar 

  309. Testa B, Kramer SD (2007) The biochemistry of drug metabolism – an introduction: part 2. Redox reactions and their enzymes. Chem Biodivers 4:257–405

    CAS  PubMed  Google Scholar 

  310. Testa B, Kramer SD (2007) The biochemistry of drug metabolism – an introduction: part 3. Reactions of hydrolysis and their enzymes. Chem Biodivers 4:2031–2122

    CAS  PubMed  Google Scholar 

  311. Testa B, Kramer SD (2008) The biochemistry of drug metabolism – an introduction: part 4. reactions of conjugation and their enzymes. Chem Biodivers 5:2171–2336

    CAS  PubMed  Google Scholar 

  312. Testa B, Kramer SD (2009) The biochemistry of drug metabolism – an introduction: part 5. Metabolism and bioactivity. Chem Biodivers 6:591–684

    CAS  PubMed  Google Scholar 

  313. Trak-Smayra V, Cazals-Hatem D, Asselah T, Duchatelle V, Degott C (2003) Prolonged cholestasis and ductopenia associated with tenoxicam. J Hepatol 39:125–128

    CAS  PubMed  Google Scholar 

  314. Trauner M, Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83:633–671

    CAS  PubMed  Google Scholar 

  315. Tujios S, Fontana RJ (2011) Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 8:202–211

    CAS  PubMed  Google Scholar 

  316. Uetrecht J (2007) Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47:513–539

    CAS  PubMed  Google Scholar 

  317. Uetrecht JP (1999) New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol 12:387–395

    CAS  PubMed  Google Scholar 

  318. van Ditzhuijsen TJ, van Haelst UJ, van Dooren-Greebe RJ, van de Kerkhof PC, Yap SH (1990) Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). J Hepatol 11:185–188

    PubMed  Google Scholar 

  319. van Heyningen C (2005) Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem 42:402–404

    PubMed  Google Scholar 

  320. Vernon G, Baranova A, Younossi ZM (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285

    CAS  PubMed  Google Scholar 

  321. Villari D, Rubino F, Corica F, Spinella S, Di Cesare E, Longo G, Raimondo G (1995) Bile ductopenia following therapy with sulpiride. Virchows Arch 427:223–226

    CAS  PubMed  Google Scholar 

  322. von Felden J, Montani M, Kessebohm K, Stickel F (2013) Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfate. Int J Clin Pharmacol Ther 51:219–223

    Google Scholar 

  323. Vreuls CP, Damink OSW, Koek GH, Winstanley A, Wisse E, Cloots RH, van den Broek MA et al (2013) Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer. Br J Cancer 108:676–680

    CAS  PubMed  PubMed Central  Google Scholar 

  324. Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, Nicod L et al (2006) CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 62:423–429

    CAS  PubMed  Google Scholar 

  325. Vuppalanchi R, Chalasani N, Saxena R (2006) Restoration of bile ducts in drug-induced vanishing bile duct syndrome due to zonisamide. Am J Surg Pathol 30:1619–1623

    PubMed  Google Scholar 

  326. Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H, Saxena R, Kleiner D et al (2010) Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 32:1174–1183

    CAS  PubMed  PubMed Central  Google Scholar 

  327. Watkins PB (2011) Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 89:788–790

    CAS  PubMed  Google Scholar 

  328. Watkins PB, Seeff LB (2006) Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 43:618–631

    PubMed  Google Scholar 

  329. Weir JF, Comfort MW (1933) Toxic cirrhosis caused by cinchophen. Arch Intern Med 52:685–724

    CAS  Google Scholar 

  330. Weiss VC, Layden T, Spinowitz A, Buys CM, Nemchausky BA, West DP, Emmons KM (1985) Chronic active hepatitis associated with etretinate therapy. Br J Dermatol 112:591–597

    CAS  PubMed  Google Scholar 

  331. Whalley S, Puvanachandra P, Desai A, Kennedy H (2007) Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin Med (Lond) 7:119–124

    Google Scholar 

  332. Whiting-O’Keefe QE, Fye KH, Sack KD (1991) Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 90:711–716

    PubMed  Google Scholar 

  333. Whittaker SJ, Amar JN, Wanless IR, Heathcote J (1982) Sulindac hepatotoxicity. Gut 23:875–877

    CAS  PubMed  PubMed Central  Google Scholar 

  334. Williams NA, Lee MG, Hanchard B, Barrow KO (1997) Hepatic cirrhosis in Jamaica. West Indian Med J 46:60–62

    CAS  PubMed  Google Scholar 

  335. Wolters LM, Van Buuren HR (2005) Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol 17:589–590

    CAS  PubMed  Google Scholar 

  336. Yang K, Kock K, Sedykh A, Tropsha A, Brouwer KL (2013) An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. J Pharm Sci 102:3037–3057

    CAS  PubMed  PubMed Central  Google Scholar 

  337. Zachariae H, Kragballe K, Sogaard H (1980) Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 102:407–412

    CAS  PubMed  Google Scholar 

  338. Zafrani ES, Bernuau D, Feldmann G (1984) Peliosis-like ultrastructural changes of the hepatic sinusoids in human chronic hypervitaminosis A: report of three cases. Hum Pathol 15:1166–1170

    CAS  PubMed  Google Scholar 

  339. Zapata Garrido AJ, Romo AC, Padilla FB (2003) Terbinafine hepatotoxicity. A case report and review of literature. Ann Hepatol 2:47–51

    PubMed  Google Scholar 

  340. Zeiss J, Merrick HW, Savolaine ER, Woldenberg LS, Kim K, Schlembach PJ (1990) Fatty liver change as a result of hepatic artery infusion chemotherapy. Am J Clin Oncol 13:156–160

    CAS  PubMed  Google Scholar 

  341. Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H (2013) Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol 25:825–829

    PubMed  Google Scholar 

  342. Zimmerman HJ (1999) Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  343. Zimmerman HJ, Ishak KG (1982) Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 2:591–597

    CAS  PubMed  Google Scholar 

  344. Zimmerman HJ, Ishak KG (1994) Non-alcoholic steatohepatitis and other forms of pseudoalcoholic liver disease. In: Hall P (Hrsg) Alcoholic liver disease. Arnold, London, S 175–198

    Google Scholar 

  345. Zimmerman HJ, Lewis JH (1995) Chemical- and toxin-induced hepatotoxicity. Gastroenterol Clin North Am 24:1027–1045

    CAS  PubMed  Google Scholar 

  346. Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC (1984) Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4:315–323

    CAS  PubMed  Google Scholar 

  347. Zollner G, Marschall HU, Wagner M, Trauner M (2006) Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 3:231–251

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Universitätsspital Basel, Basel, Schweiz

    Prof. Dr. Luigi Terracciano

  2. Institut für Pathologie, Kantonsspital Baden, Baden, Schweiz

    Priv.-Doz. Dr. Sylvia Stadlmann

  3. Gilab AG, Allschwil, Schweiz

    Prof. Dr. Luigi Tornillo

Authors
  1. Prof. Dr. Luigi Terracciano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Priv.-Doz. Dr. Sylvia Stadlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. Luigi Tornillo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luigi Terracciano .

Editor information

Editors and Affiliations

  1. Institut für Pathologie, Ruhr-Universität Bochem, Bochum, Nordrhein-Westfalen, Germany

    Andrea Tannapfel

  2. Konsultationszentrum für Pankreas- und Endokrine Tumore, Technische Universität München, München, Germany

    Günter Klöppel

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Terracciano, L., Stadlmann, S., Tornillo, L. (2020). Medikamentös-toxischer Leberschaden (DILI). In: Tannapfel, A., Klöppel, G. (eds) Pathologie. Pathologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-04557-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-04557-8_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-04556-1

  • Online ISBN: 978-3-642-04557-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation